One Orchard launches InfraMed, a healthcare infrastructure platform seeded with 25 assets
The new holding company's first platform launches with an existing 25-asset medical outpatient portfolio and Pantheon as its lead institutional backer.
Connect CRE reports that One Orchard, a New York-based investment firm and holding company, has launched with a mandate to concentrate capital into fully integrated, proprietary real asset platforms. Its first move is InfraMed Properties, a healthcare infrastructure strategy focused on acquiring and managing critical medical outpatient facilities leased to leading healthcare systems and specialty care providers.
InfraMed comes to market with a 25-asset portfolio already in place. It was formed with REDICO, a vertically integrated real estate investment, development and operating company with a healthcare track record stretching back 60 years. One Orchard's investment in the platform is supported by its institutional limited partners, led by Pantheon, a global private markets investor with $84 billion in assets under management.
Elliott said that he and Bradley Guz, the co-founders of One Orchard, have spent the past 15 years investing in real assets and platforms. More than $10 billion has been deployed in that time. "The formation of One Orchard and InfraMed is the culmination of our prior experiences investing over $10 billion in real assets and platforms over the past 15 years, and our strong view on the need for a more integrated approach in a new era of private markets and real assets investing."
InfraMed starts with a portfolio intact
One Orchard is structured around a simple wager: integration matters. Its platforms come with assets attached rather than a list of deals. InfraMed has 25 properties and REDICO's operating experience, so Pantheon-led capital enters a defined business on day one. For limited partners, the money buys an existing portfolio, not a promise of future deals. Whether InfraMed becomes the model, and which real asset niche One Orchard targets next, is the open question.